Back to search

University of British Columbia

Mass spectrometry-based molecular investigation of dual AXL and BCL-2 inhibition in acute myeloid leukemia

Abstract

dc:description

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy marked by frequent relapse and therapeutic resistance. Although the BCL-2 inhibitor venetoclax (VEN) has improved patient outcomes, drug resistance limits its efficacy. Overexpression of AXL, a member of the TAM family of receptor tyrosine kinases, has been linked to poor outcomes in AML. A recent study from our lab demonstrated that AXL activity is upregulated in AML stem/progenitor cells, particularly in MLL-mutant cells. Combining a newly developed selective AXL inhibitor (SLC-391) with BCL-2 inhibition sensitized these cells to VEN, yielding strong synergistic effects in vitro and in PDX models. However, the underlying mechanism of this synergy remains unclear. This study investigated the molecular basis of synergistic cell death induced by combined inhibition of AXL and BCL-2 in MLL-rearranged AML models. Quantitative mass spectrometry-based proteomics identified a greater number of differentially expressed proteins following dual inhibition of AXL and BCL-2 than with either inhibitor alone in AML cells. Gene set enrichment analysis showed downregulation of mRNA processing and cytoskeletal pathways and upregulation of cellular transport and energy metabolism. Four promising candidate proteins, including STMN1, HCLS1, LCP1, and AHNAK, involved in the regulation of cytoskeletal remodeling and survival signaling, were selected for functional validation. Interestingly, shRNA knockdown demonstrated that STMN1 and HCLS1 depletion significantly reduced cell viability, increased apoptosis, and enhanced drug sensitivity, particularly in VEN-resistant cells, while LCP1 and AHNAK showed cell context-dependent effects. Western blot analyses further demonstrated alteration of key proteins in survival signaling pathways, including β-catenin, AKT, STAT3, and MCL-1, following protein knockdown, providing mechanistic evidence linking cytoskeletal regulation to AXL-BCL-2-mediated signaling networks in AML. In conclusion, this study uncovered several key proteins and pathways that were differentially expressed under combined inhibition of AXL and BCL-2 in AML cells. Among these, the cytoskeletal regulators STMN1 and HCLS1 were shown to mediate AML cell survival and drug sensitivity, suggesting that they may contribute to resistance to BCL-2 inhibition and could serve as therapeutic targets in MLL-mutated AML. These newly identified candidates may also serve as biomarkers to predict patients’ responses to AML therapies.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Interdisciplinary Oncology
Grantor dc:publisher
University of British Columbia
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Guo, Hongyu
Contributors dc:contributor
  • Jiang, Xiaoyan

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/94491

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Guo, Hongyu. Mass spectrometry-based molecular investigation of dual AXL and BCL-2 inhibition in acute myeloid leukemia. master's thesis, University of British Columbia, 2026. http://hdl.handle.net/2429/94491